Occlutech is a leading specialist provider of minimally invasive structural heart devices, with a mission to improve the quality of life for people with heart conditions. The vision is to become the leading global specialist in cardiac devices, addressing congenital heart defects, stroke prevention and heart failure. Since 2003, the company has developed, manufactured, and commercialized occluders and interatrial shunt products. Occlutech has a proven portfolio, based on proprietary technology, and holds over 200 patents with over 200,000 products sold. The company markets and sells its products in over 80 countries. The company has around 330 employees and is a public limited liability company registered in Switzerland.

For more information, connect with Occlutech on LinkedIn.

Website:
https://occlutech.com/

E-Mail:
info@occlutech.com

Occlutech proudly marked its entry into the world’s largest structural heart disease market with the official U.S. launch of the Occlutech ASD Occluder in September 2024. Following FDA approval in December 2023, this milestone represents our first product launch in the United States. The Occlutech ASD Occluder provides a safe and effective solution for the closure of ostium secundum-type atrial septal defects (ASD), a common heart condition that can lead to complications such as stroke and heart failure.  For U.S. important safety information on the Occlutech ASD Occluder, visit  Occlutech - Every beat counts

Not available in all geographies. Please contact your Occlutech representative about the availability of Occlutech products in your area. © Occlutech. All rights reserved. Occlutech is a registered trademark.

MM_GEN_014_01